This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of BPD in Premature Infants

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Medipost Co Ltd.
ClinicalTrials.gov Identifier:
NCT01828957
First received: April 2, 2013
Last updated: April 18, 2017
Last verified: April 2017
April 2, 2013
April 18, 2017
April 2013
August 2015   (Final data collection date for primary outcome measure)
Incidence of BPD (moderate to severe) or mortality at 36 weeks PMA [ Time Frame: 36 weeks PMA ]
Incidence of BPD (moderate to severe) or mortality rate at 36 weeks PMA
Same as current
Complete list of historical versions of study NCT01828957 on ClinicalTrials.gov Archive Site
  • Intubation duration [ Time Frame: 36 weeks PMA ]
  • Incidence of BPD [ Time Frame: 28-days since birth ]
  • Survival rate [ Time Frame: 28-days since birth, 36 weeks PMA, and termination of the trial ]
  • Duration of ventilator dependence [ Time Frame: Week 24 ]
  • Duration of CPAP treatment [ Time Frame: Week 24 ]
  • Postnatal steroid use (%) for the purpose of ventilator weaning [ Time Frame: Week 24 ]
  • Cumulative duration of oxygen use [ Time Frame: Week 24 ]
  • Incidence of Retinopathy of Prematurity (ROP) of Grade III or more [ Time Frame: Week 24 ]
  • Retinopathy of Prematurity (ROP) that require treatment with avastin or laser [ Time Frame: Week 24 ]
  • Growth velocity (Z-score) [ Time Frame: Week 24 ]
  • Length of stay prior to the first discharge from the hospital [ Time Frame: duration of the hospital stay, an expected average of approximately 3 months since birth ]
  • Incidence of adverse events [ Time Frame: Week 24 ]
  • Clinically significant laboratory findings [ Time Frame: Week 24 ]
  • Incidence of pneumothorax that require intubation [ Time Frame: Week 24 ]
  • Incidence of moderate to severe pulmonary hemorrhage [ Time Frame: Week 24 ]
  • Incidence of intraventricular hemorrhage of grade 3 or more [ Time Frame: Week 24 ]
Same as current
Not Provided
Not Provided
 
Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of BPD in Premature Infants
Randomized, Double-blind, Multi-center, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Pneumostem® Versus a Control Group for Treatment of Bronchopulmonary Dysplasia in Premature Infants
The objective of this study is to evaluate the efficacy and safety of a single intratracheal administration of Pneumostem® for treatment of Bronchopulmonary Dysplasia (BPD) in high-risk premature infants by comparing Pneumostem-treated group with a control group.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Bronchopulmonary Dysplasia
  • Biological: Pneumostem®
    Other Name: Human umbilical cord blood-derived mesenchymal stem cells
  • Other: Normal Saline
  • Experimental: Pneumostem®
    A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)
    Intervention: Biological: Pneumostem®
  • Placebo Comparator: normal saline
    A single intratracheal administration of normal saline
    Intervention: Other: Normal Saline
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
70
August 2015
August 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age: 5 - 14 days since birth
  • Fetal gestational age: ≥23 weeks and <29 weeks
  • Birth weight: ≥500g and ≤1250g
  • Premature infant of equal to or less than 2 weeks of age who is receiving a ventilator therapy at a rate of > 12 breath/min and > 25% oxygen
  • Patient whose ventilator setting has not been changed and who has shown aggravation of the illness within the 24 hours prior to the study enrollment
  • Patient with a written consent form signed by a legal representative or a parent upon explanation of the clinical trial

Exclusion Criteria:

  • Patient with concurrent cyanotic or acyanotic congenital heart diseases, except for patent ductus arteriosus
  • Patient with a concurrent severe lung malformation (i.e. Pulmonary hypoplasia, congenital diaphragmatic hernia, congenital cystic lung disease)
  • Patient with a concurrent severe lung malformation with chromosome anomalies (i.e. Edward syndrome, Patau syndrome, Down syndrome, etc) or severe congenital malformation (Hydrocephalus, Encephalocele, etc)
  • Patient with a concurrent severe congenital infection (i.e. Herpes, Toxoplasmosis, Rubella, Syphilis, AIDS, etc)
  • Patient withCRP > 30 mg/dL; Severe sepsis or shock
  • Patient who is scheduled for or expected to undergo a surgical procedure 72 hours prior to/following the administration of the study drug
  • Patient who has been administered with a surfactant within the 24 hours prior to the administration of the study drug
  • Patient with severe intracranial hemorrhage ≥ grade 3 or 4
  • Patient with active pulmonary hemorrhage or active air leak syndrome at the time of screening
  • Patient with a history of participating in other clinical studies
  • Patient who is allergic to Gentamicin
  • Patient who is considered inappropriate to participate in the study by the investigator
Sexes Eligible for Study: All
up to 14 Days   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT01828957
MP-CR-009
Yes
Not Provided
Not Provided
Medipost Co Ltd.
Medipost Co Ltd.
Not Provided
Principal Investigator: Won-Soon Park, MD, PhD Department of Pediatrics, Samsung Medical Center
Principal Investigator: Ai-Rhan Kim Department of Neonatology, Asan Medical Center
Medipost Co Ltd.
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP